Agenus (4-Antibody)

Broad platform of antibodies and vaccines targeting the immune system for cancer therapy 

Agenus is developing a clinical pipeline of proprietary cancer vaccines and monoclonal antibodies for use individually and in combination in the treatment of a range of cancers. The company has established collaborations with Merck and Incyte on some of its checkpoint modulators.

CEO  Garo Armen

www.agenusbio.com

Advent Contact  Shahzad Malik

Agenus acquired 4-Antibody, an Advent portfolio company, in 2014. Agenus is listed on NASDAQ.
Publicly Listed
5 February 2014 in Agenus, Press Release, Publicly Listed

Agenus Prices Public Offering of Common Stock

Press Release.   Lexington, MA (February 5, 2014): Agenus Inc. (Nasdaq: AGEN) today announced the pricing of an underwritten public offering of 19,335,653 primary shares of its common stock at…
Read More
13 January 2014 in Agenus, Press Release, Publicly Listed

Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG

Press Release.   4-Antibody has a powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of  molecular targets Lead programs target six immune checkpoint molecules…
Read More